

10120204

JC09 Rec'd PCT/PTO Q6, OCT 2005

"Express Mail" mailing label number

EV 393129005 US

Date of Deposit

Oct 06, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DeeDee Thomas

Printed Name

DeeDee Thomas

Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Gregory Lee Durst, et al.

For: Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists

Docket No.: X-16067

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b),  
Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

  
John C. Demeter  
Attorney for Applicant(s)  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

August 25, 2005

10/552504

JC09 Rec'd PCT/PTO 06 OCT 2005

Sheet 1 of 2

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16067	Serial No
	First Applicant Gregory Lee Durst	
	Filing Date	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 6,630,508			
	AB	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA	WO 01/64665	September 7, 2001	Akzo Nobel N.V.		
	BB	WO 03/044006	May 30, 2003	Eli Lilly and Company		
	BC	WO 99/02512	January 21, 1999	Novo Nordisk A/S		
	BD	WO 01/72713	October 4, 2001	Akzo Nobel N.V.		
	BE	WO 03/051805	June 26, 2003	Wyeth		
	BF	WO 01/49673	July 12, 2001	Signal Pharmaceuticals, Inc.		
	BG	WO 97/09348	September 9, 1996	Karo Bio AB		
	BH	GB 2 361 642	October 31, 2001	Karo Bio AB		
	BI					

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/552204

JC09 Rec'd PCT/PTO Q 6 OCT 2005

Sheet 2 of 2

FORM PTO 1449 (modified)		Atty. Docket No. X-16067	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant Gregory Lee Durst	
		Filing Date	Group

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.		T <sup>6</sup>
	CA	Anderson, et al., "Synthesis of 6,9-bisnormethyl-8-methoxy-12,13-epoxy-6,8,10-trichothecatriene," Journal of Organic Chemistry, American Chemical Society, Easton, U.S., Vol. 42, No. 6, pgs. 1045-1050 (1977)		
	CB	Oude-Alink, et al., "Photolysis of 2-keto-2,3-dihydrobenzofurans, o-hydroxystyrenes and 1-o-hydroxyphenyl)-1,5-hexadienes," Journal of Organic Chemistry, American Chemical Society, Easton, U.S., Vol. 38, No. 11, pgs. 1993-2001 (1973)		
	CC	Shrestha, et al., "Facile synthesis of the fused 6-6-5 ring system containing chroman ring from 2-(1-hydroxy-5-alkenyl)phenol derivatives via intramolecular inverse-electron-demanddiels-alder reaction," Bulletin of the Chemical Society of Japan, Japan Publications Trading Co., Tokyl, JP, Vol. 72, No. 1, pgs. 73-83 (1999)		
	CD	Welhua, et al., "A role for estrogen receptor $\beta$ in the regulation of growth of the ventral prostate," PNAS, Vol. 98, No. 11, pgs. 6330-6335 (2001)		
	CE	Mortensen, et al., "Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor $\alpha$ ," Journal of Medicinal Chemistry, A-K, Page Est. 10:8 (2001)		
	CF	Meyers, "Estrogen receptor- $\beta$ potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues," Journal of Medicinal Chemistry, A-V, Page Est. 21:3 (2001)		
	CG			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.